| 2027-02-01in 160 d | An Open-label, Single-arm Interventional Study to Evaluate the Safety and Efficacy of a Probiotic-containing Cream in Children With Dry Skin | BIOG-B.STBioGaia AB | Not applicable | Dry Skin | Not yet recruiting |
| 2027-02-01in 160 d | Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | BMYBristol-Myers Squibb | Phase 1 | Acute Myeloid Leukemia | Recruiting |
| 2027-02-01in 160 d | CGUARDIANS III IDE Pivotal Trial | NSPRInspireMD | Not applicable | Carotid Artery Stenosis | Not yet recruiting |
| 2027-02-01in 160 d | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | TVRDTvardi Therapeutics, Incorporated | Phase 1/2 | Hepatocellular Carcinoma | Recruiting |
| 2027-02-02in 161 d | A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants | BIIBBiogen | Phase 1 | Healthy Volunteer | Recruiting |
| 2027-02-02in 161 d | Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib | NUVBNuvation Bio Inc. | Phase 1 | Healthy Adult Participants | Not yet recruiting |
| 2027-02-02in 161 d | A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | VRTXVertex Pharmaceuticals Incorporated | Phase 1/2 | Myotonic Dystrophy Type 1 (DM1) | Active, not recruiting |
| 2027-02-03in 162 d | Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care | AZNAstraZeneca | Phase 4 | Asthma | Active, not recruiting |
| 2027-02-04in 163 d | A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 | AZNAstraZeneca | Phase 1 | Hepatic Impairment | Recruiting |
| 2027-02-04in 163 d | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug | MLTXMoonLake Immunotherapeutics AG | Phase 3 | Psoriatic Arthritis | Active, not recruiting |
| 2027-02-05in 164 d | Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium) | BIIBBiogen | — | Muscular Atrophy, Spinal | Active, not recruiting |
| 2027-02-05in 164 d | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | BMYBristol-Myers Squibb | Phase 2 | Lung Cancer | Active, not recruiting |
| 2027-02-05in 164 d | A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A | NVONovo Nordisk A/S | Phase 1 | Hemophilia A | Recruiting |
| 2027-02-05in 164 d | A Post Approval Multicenter 10 Year Follow-up Observational Trial of Marketed Product - MP01 vs. Surgical Standard of Care (SSOC) Used for the Treatment of Joint Surface Lesions of the Knee | SNNSmith & Nephew, Inc. | — | Knee Injuries, Joint Surface Knee Lesions | Enrolling by invitation |
| 2027-02-07in 166 d | A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | INSMInsmed Incorporated | Phase 1 | Hepatic Impairment | Recruiting |
| 2027-02-09in 168 d | A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy | HLUN-B.COH. Lundbeck A/S | Phase 1 | Narcolepsy | Recruiting |
| 2027-02-09in 168 d | Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | REGNRegeneron Pharmaceuticals | Phase 2 | Atrial Fibrillation | Recruiting |
| 2027-02-09in 168 d | Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa | SNYSanofi | Phase 2 | Hidradenitis Suppurativa | Recruiting |
| 2027-02-11in 170 d | A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | AZNAstraZeneca | Phase 2 | Sepsis, Acute Kidney Injury | Recruiting |
| 2027-02-12in 171 d | Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN) | 4568.TDaiichi Sankyo | — | Lung Cancer | Recruiting |
| 2027-02-12in 171 d | A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa | OCGNOcugen | Phase 3 | Retinitis Pigmentosa | Active, not recruiting |
| 2027-02-12in 171 d | A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults | PFEPfizer | Phase 1 | Healthy | Not yet recruiting |
| 2027-02-14in 173 d | A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy | 4523.TEisai Inc. | Phase 2 | Narcolepsy | Recruiting |
| 2027-02-14in 173 d | Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed) | AZNAstraZeneca | — | Castration-Resistant Prostate Cancer | Recruiting |
| 2027-02-15in 174 d | Feasibility Study of the FARAFLEX Mapping and PFA System | BSXBoston Scientific Corporation | Not applicable | Atrial Fibrillation | Recruiting |
| 2027-02-15in 174 d | FARAPULSE Workflow Assessment Registry | BSXBoston Scientific Corporation | — | Atrial Fibrillation | Active, not recruiting |
| 2027-02-15in 174 d | Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide | GUTSFractyl Health Inc. | Not applicable | Obesity | Active, not recruiting |
| 2027-02-15in 174 d | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis | MRNAModernaTX, Inc. | Phase 3 | Acute Gastroenteritis, Norovirus Acute Gastroenteritis | Active, not recruiting |
| 2027-02-15in 174 d | Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. | PFEPfizer | — | Atopic Dermatitis | Recruiting |
| 2027-02-17in 176 d | Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | AMGNAmgen | Phase 1 | Prostate Cancer | Recruiting |
| 2027-02-17in 176 d | An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | SNYSanofi | Phase 3 | Chronic Rhinosinusitis | Active, not recruiting |
| 2027-02-18in 177 d | Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | AZNAstraZeneca | Phase 3 | Chronic Kidney Disease | Active, not recruiting |
| 2027-02-20in 179 d | REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults | REGNRegeneron Pharmaceuticals | Phase 3 | Venous Thromboembolism (VTE) | Recruiting |
| 2027-02-22in 181 d | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) | AZNAstraZeneca | Phase 3 | Cancer | Active, not recruiting |
| 2027-02-22in 181 d | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | AZNAstraZeneca | Phase 2/3 | Dyslipidaemia | Active, not recruiting |
| 2027-02-22in 181 d | Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System | PODDInsulet Corporation | Not applicable | Type 2 Diabetes | Recruiting |
| 2027-02-22in 181 d | Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity | REGNRegeneron Pharmaceuticals | Phase 1 | Obesity | Recruiting |
| 2027-02-23in 182 d | Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | AZNAstraZeneca | Phase 3 | Lupus Nephritis | Active, not recruiting |
| 2027-02-23in 182 d | Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians | NVONovo Nordisk A/S | — | Liver Disease | Recruiting |
| 2027-02-23in 182 d | A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function | PFEPfizer | Phase 1 | Hepatic Impairment, Healthy | Recruiting |
| 2027-02-25in 184 d | Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use. | PFEPfizer | — | Multiple Myeloma | Active, not recruiting |
| 2027-02-26in 185 d | A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults | ARDXArdelyx | Phase 3 | Chronic Idiopathic Constipation (CIC) | Recruiting |
| 2027-02-26in 185 d | Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants | VRTXVertex Pharmaceuticals Incorporated | Phase 1 | Pain | Recruiting |
| Feb 2027≤ 187 d | A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis | 068270.KSCelltrion | Phase 3 | Multiple Sclerosis | Recruiting |
| Feb 2027≤ 187 d | A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer | 068270.KSCelltrion | Phase 3 | Non Squamous Non Small Cell Lung Cancer | Active, not recruiting |
| Feb 2027≤ 187 d | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | ABBVAbbVie | Phase 1/2 | Acute Myeloid Leukemia | Active, not recruiting |
| Feb 2027≤ 187 d | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | ABBVAbbVie | Phase 1 | Diffuse Large B-Cell Lymphoma | Recruiting |
| Feb 2027≤ 187 d | First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | ABBVAbbVie | Phase 1 | Endometrial Cancer | Active, not recruiting |
| Feb 2027≤ 187 d | An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World | ABBVAbbVie | — | Atopic Dermatitis | Active, not recruiting |
| Feb 2027≤ 187 d | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | ABBVAbbVie | Phase 1 | Multiple Myeloma | Active, not recruiting |
| Feb 2027≤ 187 d | A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | ABBVAbbVie | Phase 2 | Ovarian Cancer | Active, not recruiting |
| Feb 2027≤ 187 d | A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) | ABBVAbbVie | Phase 1 | Hepatocellular Carcinoma | Active, not recruiting |
| Feb 2027≤ 187 d | A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab | ABBVAbbVie | Phase 2 | Hidradenitis Suppurativa | Recruiting |
| Feb 2027≤ 187 d | A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | ABBVAbbVie | Phase 2 | Rheumatoid Arthritis | Recruiting |
| Feb 2027≤ 187 d | A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder | ABBVAbbVie | Phase 1 | Bipolar Disorder | Not yet recruiting |
| Feb 2027≤ 187 d | A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants | ABBVAbbVie | Phase 1 | Healthy Volunteer | Recruiting |
| Feb 2027≤ 187 d | Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause | ABCLAbCellera Biologics Inc. | Phase 1/2 | Vasomotor Symptoms Associated With Menopause, Healthy Volunteers | Active, not recruiting |
| Feb 2027≤ 187 d | A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa | ALM.MCAlmirall, S.A. | Phase 2 | Hidradenitis Suppurativa | Recruiting |
| Feb 2027≤ 187 d | AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis | AMLXAmylyx Pharmaceuticals Inc. | Phase 1 | ALS | Recruiting |
| Feb 2027≤ 187 d | A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | ARWRArrowhead Pharmaceuticals | Phase 1/2 | Obesity | Recruiting |
| Feb 2027≤ 187 d | HEAL-IST IDE Trial | ATRCAtriCure, Inc. | Not applicable | Inappropriate Sinus Tachycardia | Active, not recruiting |
| Feb 2027≤ 187 d | BoxX-NoAF Clinical Trial | ATRCAtriCure, Inc. | Not applicable | Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative | Recruiting |
| 2027-02-28in 187 d | Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease | AZNAstraZeneca | Not applicable | Respiratory Syncytial Virus | Recruiting |
| 2027-02-28in 187 d | Multicenter, Observational, Descriptive Study of the Diagnosis, Course and Treatment of Patients With SLE in Routine Practice in Kazakhstan: a Registry Study With Retrospective and Prospective Components. | AZNAstraZeneca | — | Description of SLE Activity in Patients in Routine Practice in the Republic of Kazakhstan, Description of the Course of SLE in Patients in the Republic of Kazakhstan, Description of Methods and Approaches to the Treatment of Patients With SLE in the Republic of Kazakhstan | Active, not recruiting |
| Feb 2027≤ 187 d | A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy | BLCOBausch & Lomb Incorporated | Phase 2 | Pain, Postoperative | Not yet recruiting |
| Feb 2027≤ 187 d | BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial | BLCOBausch & Lomb Incorporated | Phase 2 | Dry Eye Disease | Not yet recruiting |
| Feb 2027≤ 187 d | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease | DNLIDenali Therapeutics Inc. | Phase 1 | Alzheimer's Disease | Recruiting |
| 2027-02-28in 187 d | The ENCIRCLE Trial | EWEdwards Lifesciences | Not applicable | Mitral Regurgitation, Mitral Valve Insufficiency | Recruiting |
| 2027-02-28in 187 d | Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease | FBRXForte Biosciences, Inc. | Phase 2 | Celiac Disease | Recruiting |
| Feb 2027≤ 187 d | A Study Testing the Safety and Effects of FB102 in Healthy Volunteers | FBRXForte Biosciences, Inc. | Phase 1 | Healthy Volunteer | Recruiting |
| Feb 2027≤ 187 d | Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) Prospective Double-Scanning Study | GEHCGE Healthcare | — | SPECT-CT | Recruiting |
| Feb 2027≤ 187 d | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | GERNGeron Corporation | Phase 1 | Myelofibrosis | Recruiting |
| Feb 2027≤ 187 d | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | GILDGilead Sciences | Phase 3 | Breast Cancer | Active, not recruiting |
| Feb 2027≤ 187 d | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | GNLXGenelux Corporation | Phase 2 | Lung Cancer | Recruiting |
| Feb 2027≤ 187 d | A Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity Sufferers | HLNHALEON | — | Dentin Hypersensitivity | Recruiting |
| 2027-02-28in 187 d | Imlifidase Prior to Kidney Transplant in Highly Sensitised Children | HNSA.STHansa Biopharma AB | Phase 2 | Kidney Transplantation in Highly Sensitized Patients | Recruiting |
| Feb 2027≤ 187 d | Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD | ICUSeaStar Medical | Not applicable | Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome | Recruiting |
| 2027-02-28in 187 d | Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea | INSPInspire Medical Systems, Inc. | Phase 3 | Obstructive Sleep Apnea | Active, not recruiting |
| Feb 2027≤ 187 d | PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717 | IONSIonis Pharmaceuticals, Inc. | Phase 1/2 | Prion Disease | Active, not recruiting |
| Feb 2027≤ 187 d | A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) | IRONDisc Medicine, Inc | Phase 2 | Polycythemia Vera (PV) | Active, not recruiting |
| Feb 2027≤ 187 d | Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY | JAZZJazz Pharmaceuticals | — | Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex | Active, not recruiting |
| Feb 2027≤ 187 d | A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | KODKodiak Sciences Inc | Phase 3 | Macular Edema Secondary to Inflammation | Recruiting |
| Feb 2027≤ 187 d | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | KRYSKrystal Biotech, Inc. | Phase 1/2 | Lung Cancer | Recruiting |
| Feb 2027≤ 187 d | A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease | LLYEli Lilly and Company | Phase 1 | Alzheimer's Disease | Recruiting |
| Feb 2027≤ 187 d | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | LLYEli Lilly and Company | Phase 1 | Ovarian Cancer | Recruiting |
| Feb 2027≤ 187 d | A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | LLYEli Lilly and Company | Phase 2 | Glioma | Active, not recruiting |
| Feb 2027≤ 187 d | A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | LLYEli Lilly and Company | Phase 3 | Obesity | Recruiting |
| Feb 2027≤ 187 d | A Study of LY3981314 in Healthy Participants | LLYEli Lilly and Company | Phase 1 | Healthy | Active, not recruiting |
| Feb 2027≤ 187 d | A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse | LLYEli Lilly and Company | Phase 2 | Smoking | Recruiting |
| Feb 2027≤ 187 d | A Study of Mirikizumab Solution (LY3074828) in Healthy Participants | LLYEli Lilly and Company | Phase 1 | Healthy | Recruiting |
| Feb 2027≤ 187 d | A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity | LLYEli Lilly and Company | Phase 1 | Obesity | Active, not recruiting |
| Feb 2027≤ 187 d | Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia | NBIXNeurocrine Biosciences | Phase 2 | Tardive Dyskinesia | Recruiting |
| 2027-02-28in 187 d | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | NTHINeonc Technologies, Inc. | Phase 1/2 | Cervical Cancer | Recruiting |
| Feb 2027≤ 187 d | A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy | NTRANatera, Inc. | Not applicable | Heart Transplant Failure and Rejection | Active, not recruiting |
| 2027-02-28in 187 d | A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea | NVONovo Nordisk A/S | — | Obesity | Enrolling by invitation |
| 2027-02-28in 187 d | ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme | PIIPolaris Group | Phase 2 | Glioblastoma | Active, not recruiting |
| 2027-02-28in 187 d | Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy | REGNRegeneron Pharmaceuticals | Phase 3 | Allergic Conjunctivitis | Recruiting |
| Feb 2027≤ 187 d | A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants | SEPNSepterna, Inc. | Phase 1 | Healthy Volunteers | Recruiting |
| 2027-02-28in 187 d | Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension | SGPSpyGlass Pharma, Inc. | Phase 1 | Glaucoma | Not yet recruiting |
| Feb 2027≤ 187 d | A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | SNDXSyndax Pharmaceuticals | Phase 1 | Acute Myeloid Leukemia | Active, not recruiting |
| Feb 2027≤ 187 d | B-FREE Chronic Babesiosis Study | SXTP60 Degrees Pharmaceuticals LLC | Phase 2 | Chronic Babesiosis | Recruiting |
| Feb 2027≤ 187 d | Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays | TEMTempus AI | — | Colorectal Cancer | Recruiting |
| Feb 2027≤ 187 d | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | XNCRXencor, Inc. | Phase 1 | Renal Cell Carcinoma | Recruiting |
